热门出版物 - 学术资源搜索

h5 指数:52
h5 中位数:69

h5 指数是指在过去整整 5 年中所发表文章的 h 指数。h 指在 2019-2023 年间发表的 h 篇文章每篇至少都被引用过 h 次的最大值。隐藏

出版物的 h5 中位数，是指出版物的 h5 指数所涵盖的所有文章获得的引用次数的中位值。隐藏

#9 Diabetes
#12 Vascular Medicine

标题/作者	引用次数	年份
Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 TR Einarson, A Acs, C Ludwig, UH Panton Cardiovascular Diabetology 17 (1), 83	227	2018
Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis C Sonesson, PA Johansson, E Johnsson, I Gause-Nilsson Cardiovascular Diabetology 15 (1), 37	180	2016
Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes SK Paul, K Klein, BL Thorsted, ML Wolden, K Khunti Cardiovascular Diabetology 14 (1), 100	136	2015
Association between insulin resistance and the development of cardiovascular disease V Ormazabal, S Nair, O Elfeky, C Aguayo, C Salomon, FA Zuñiga Cardiovascular Diabetology 17 (1), 122	136	2018
Oxidative stress, inflammation, endothelial dysfunction and incidence of type 2 diabetes AO Odegaard, DR Jacobs, OA Sanchez, DC Goff, AP Reiner, MD Gross Cardiovascular Diabetology 15 (1), 51	115	2016
Low birth weight leads to obesity, diabetes and increased leptin levels in adults: the CoLaus study FR Jornayvaz, P Vollenweider, M Bochud, V Mooser, G Waeber, ... Cardiovascular Diabetology 15 (1), 73	105	2016
Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study A Solini, L Giannini, M Seghieri, E Vitolo, S Taddei, L Ghiadoni, RM Bruno Cardiovascular Diabetology 16 (1), 138	98	2017
Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes J Habibi, AR Aroor, JR Sowers, G Jia, MR Hayden, M Garro, B Barron, ... Cardiovascular Diabetology 16 (1), 9	94	2017
Diastolic dysfunction in the diabetic continuum: association with insulin resistance, metabolic syndrome and type 2 diabetes R Fontes-Carvalho, R Ladeiras-Lopes, P Bettencourt, A Leite-Moreira, ... Cardiovascular Diabetology 14 (1), 4	91	2015
Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events J Rosenstock, N Marx, D Neubacher, T Seck, S Patel, HJ Woerle, ... Cardiovascular Diabetology 14 (1), 57	89	2015
Oxidative stress and inflammation as central mediators of atrial fibrillation in obesity and diabetes BS Karam, A Chavez-Moreno, W Koh, JG Akar, FG Akar Cardiovascular Diabetology 16 (1), 1-9	88	2017
Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study R Nishimura, Y Tanaka, K Koiwai, K Inoue, T Hach, A Salsali, SS Lund, ... Cardiovascular Diabetology 14 (1), 11	86	2015
Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study F Shigiyama, N Kumashiro, M Miyagi, K Ikehara, E Kanda, H Uchino, ... Cardiovascular Diabetology 16 (1), 84	86	2017
Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology V Gyberg, D De Bacquer, G De Backer, C Jennings, K Kotseva, L Mellbin, ... Cardiovascular Diabetology 14 (1), 1-11	83	2015
Diagnostic approaches for diabetic cardiomyopathy A Lorenzo-Almorós, J Tuñón, M Orejas, M Cortés, J Egido, Ó Lorenzo Cardiovascular Diabetology 16 (1), 1-14	82	2017
Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events KC Ferdinand, FT Botros, CM Atisso, PT Sager Cardiovascular Diabetology 15 (1), 38	80	2016
Metformin improves the angiogenic functions of endothelial progenitor cells via activating AMPK/eNOS pathway in diabetic mice JW Yu, YP Deng, X Han, GF Ren, J Cai, GJ Jiang Cardiovascular Diabetology 15 (1), 88	80	2016
Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome H Kusaka, N Koibuchi, Y Hasegawa, H Ogawa, S Kim-Mitsuyama Cardiovascular Diabetology 15 (1), 157	77	2016
Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes EZ Fisman, A Tenenbaum Cardiovascular Diabetology 14 (1), 1-13	77	2015
Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications S Yamagishi, K Fukami, T Matsui Cardiovascular Diabetology 14 (1), 1-12	75	2015

1 - 20

计算机程序会自动估算并确定日期和引用次数。